{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T14:56:49Z","timestamp":1778425009187,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peritoneal dissemination is a particular form of metastasis typically observed in ovarian cancer and the major cause for poor patient\u2019s outcome. Identification of the molecular players involved in ovarian cancer dissemination can offer an approach to develop treatment strategies to improve clinical prognosis. Here, we identified mesothelin (MSLN) as a crucial protein in the multistep process of peritoneal dissemination of ovarian cancer. We demonstrated that MSLN is overexpressed in primary and matched peritoneal metastasis of high-grade serous carcinomas (HGSC). Using several genetically engineered ovarian cancer cell lines, resulting in loss or gain of function, we found that MSLN increased cell survival in suspension and invasion of tumor cells through the mesothelial cell layer in vitro. Intraperitoneal xenografts established with MSLN<jats:sup>high<\/jats:sup> ovarian cancer cell lines showed enhanced tumor burden and spread within the peritoneal cavity. These findings provide strong evidences that MSLN is a key player in ovarian cancer progression by triggering peritoneal dissemination and provide support for further clinical investigation of MSLN as a therapeutic target in HGSC.<\/jats:p>","DOI":"10.1038\/s41389-020-00246-2","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T17:54:46Z","timestamp":1593626086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9340-3612","authenticated-orcid":false,"given":"Ricardo","family":"Coelho","sequence":"first","affiliation":[]},{"given":"Sara","family":"Ricardo","sequence":"additional","affiliation":[]},{"given":"Ana Lu\u00edsa","family":"Amaral","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3678-3815","authenticated-orcid":false,"given":"Yen-Lin","family":"Huang","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Pedro","family":"Neves","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0570-2277","authenticated-orcid":false,"given":"Nuno","family":"Mendes","sequence":"additional","affiliation":[]},{"given":"M\u00f3nica Nu\u00f1ez","family":"L\u00f3pez","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Bartosch","sequence":"additional","affiliation":[]},{"given":"Ver\u00f3nica","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Portugal","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8597-3474","authenticated-orcid":false,"given":"Jos\u00e9 Manuel","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Viola","family":"Heinzelmann-Schwarz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0446-1942","authenticated-orcid":false,"given":"Francis","family":"Jacob","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4207-9258","authenticated-orcid":false,"given":"Leonor","family":"David","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"246_CR1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","volume":"11","author":"DS Tan","year":"2006","unstructured":"Tan, D. S., Agarwal, R. & Kaye, S. B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 11, 925\u2013934 (2006).","journal-title":"Lancet Oncol."},{"key":"246_CR2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(04)15841-8","volume":"9414","author":"D Li","year":"2004","unstructured":"Li, D., Xie, K., Wolff, R. & Abbruzzese, J. L. Pancreatic cancer. Lancet 9414, 1049\u20131057 (2004).","journal-title":"Lancet"},{"key":"246_CR3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"3","author":"I Thomassen","year":"2014","unstructured":"Thomassen, I. et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int. J. Cancer 3, 622\u2013628 (2014).","journal-title":"Int. J. Cancer"},{"key":"246_CR4","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.3748\/wjg.v22.i30.6829","volume":"30","author":"M Kanda","year":"2016","unstructured":"Kanda, M. & Kodera, Y. Molecular mechanisms of peritoneal dissemination in gastric cancer. World J. Gastroenterol. 30, 6829\u20136840 (2016).","journal-title":"World J. Gastroenterol."},{"key":"246_CR5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1369\/0022155417742897","volume":"2","author":"J van Baal","year":"2018","unstructured":"van Baal, J. et al. Development of peritoneal carcinomatosis in epithelial ovarian cancer: a review. J. Histochem. Cytochem. 2, 67\u201383 (2018).","journal-title":"J. Histochem. Cytochem."},{"key":"246_CR6","first-page":"415","volume":"6","author":"RC Bast Jr.","year":"2009","unstructured":"Bast, R. C. Jr., Hennessy, B. & Mills, G. B. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 6, 415\u2013428 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"246_CR7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","volume":"3","author":"R Hassan","year":"2005","unstructured":"Hassan, R., Kreitman, R. J., Pastan, I. & Willingham, M. C. Localization of mesothelin in epithelial ovarian cancer. Appl.Immunohistochem. Mol. Morphol. 3, 243\u2013247 (2005).","journal-title":"Appl.Immunohistochem. Mol. Morphol."},{"key":"246_CR8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","volume":"1","author":"K Chang","year":"1996","unstructured":"Chang, K. & Pastan, I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl Acad. Sci. USA 1, 136\u2013140 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"246_CR9","first-page":"3862","volume":"12","author":"P Argani","year":"2001","unstructured":"Argani, P. et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 12, 3862\u20133868 (2001).","journal-title":"Clin. Cancer Res."},{"key":"246_CR10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/bjc.2012.235","volume":"1","author":"T Einama","year":"2012","unstructured":"Einama, T. et al. Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br. J. Cancer 1, 137\u2013142 (2012).","journal-title":"Br. J. Cancer"},{"key":"246_CR11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","volume":"3","author":"K Chang","year":"1992","unstructured":"Chang, K., Pastan, I. & Willingham, M. C. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int. J. Cancer 3, 373\u2013381 (1992).","journal-title":"Int. J. Cancer"},{"key":"246_CR12","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","volume":"10","author":"A Rump","year":"2004","unstructured":"Rump, A. et al. Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 10, 9190\u20139198 (2004).","journal-title":"J. Biol. Chem."},{"key":"246_CR13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/BJ20110282","volume":"2","author":"MC Chang","year":"2012","unstructured":"Chang, M. C. et al. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways. Biochem. J. 2, 293\u2013302 (2012).","journal-title":"Biochem. J."},{"key":"246_CR14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","volume":"7","author":"U Bharadwaj","year":"2011","unstructured":"Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C. & Yao, Q. Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 7, 1013\u20131024 (2011).","journal-title":"Carcinogenesis"},{"key":"246_CR15","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjc.6604964","volume":"7","author":"WF Cheng","year":"2009","unstructured":"Cheng, W. F. et al. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br. J. Cancer 7, 1144\u20131153 (2009).","journal-title":"Br. J. Cancer"},{"key":"246_CR16","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1177\/030006051204000608","volume":"6","author":"Y Wang","year":"2012","unstructured":"Wang, Y., Wang, L., Li, D., Wang, H. B. & Chen, Q. F. Mesothelin promotes invasion and metastasis in breast cancer cells. J. Int. Med. Res. 6, 2109\u20132116 (2012).","journal-title":"J. Int. Med. Res."},{"key":"246_CR17","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","volume":"9","author":"EL Servais","year":"2012","unstructured":"Servais, E. L. et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin. Cancer Res. 9, 2478\u20132489 (2012).","journal-title":"Clin. Cancer Res."},{"key":"246_CR18","doi-asserted-by":"crossref","unstructured":"Matulonis, U. A. et al. Ovarian cancer. Nat. Rev. Dis. Primer. 2, 16061 (2016).","DOI":"10.1038\/nrdp.2016.61"},{"key":"246_CR19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00404-013-3114-3","volume":"2","author":"I Meinhold-Heerlein","year":"2014","unstructured":"Meinhold-Heerlein, I. & Hauptmann, S. The heterogeneity of ovarian cancer. Arch. Gynecol. Obstet. 2, 237\u2013239 (2014).","journal-title":"Arch. Gynecol. Obstet."},{"key":"246_CR20","doi-asserted-by":"crossref","unstructured":"Ahmed N., Stenvers K. L. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front. Oncol. 3, 256(2013).","DOI":"10.3389\/fonc.2013.00256"},{"key":"246_CR21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","volume":"4","author":"SL Sangisetty","year":"2012","unstructured":"Sangisetty, S. L. & Miner, T. J. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J. Gastrointest. Surg. 4, 87\u201395 (2012).","journal-title":"World J. Gastrointest. Surg."},{"key":"246_CR22","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"16","author":"RW Tothill","year":"2008","unstructured":"Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 16, 5198\u20135208 (2008).","journal-title":"Clin. Cancer Res."},{"key":"246_CR23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/path.2547","volume":"2","author":"C Denkert","year":"2009","unstructured":"Denkert, C. et al. A prognostic gene expression index in ovarian cancer-validation across different independent data sets. J. Pathol. 2, 273\u2013280 (2009).","journal-title":"J. Pathol."},{"key":"246_CR24","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/0008-5472.CAN-05-3694","volume":"3","author":"ND Hendrix","year":"2006","unstructured":"Hendrix, N. D. et al. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res. 3, 1354\u20131362 (2006).","journal-title":"Cancer Res."},{"key":"246_CR25","doi-asserted-by":"crossref","unstructured":"Prat, J. New insights into ovarian cancer pathology. Ann. Oncol. 23, x111-x117 (2012).","DOI":"10.1093\/annonc\/mds300"},{"key":"246_CR26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"1","author":"LC Peres","year":"2019","unstructured":"Peres, L. C. et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J. Natl Cancer Inst. 1, 60\u201368 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"246_CR27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","volume":"6","author":"R Perets","year":"2013","unstructured":"Perets, R. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 6, 751\u2013765 (2013).","journal-title":"Cancer Cell."},{"key":"246_CR28","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"3","author":"E Lengyel","year":"2010","unstructured":"Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 3, 1053\u20131064 (2010).","journal-title":"Am. J. Pathol."},{"key":"246_CR29","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1038\/onc.2009.139","volume":"31","author":"S Mori","year":"2009","unstructured":"Mori, S. et al. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 31, 2796\u20132805 (2009).","journal-title":"Oncogene"},{"key":"246_CR30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.21873\/cgp.20004","volume":"6","author":"UH Weidle","year":"2016","unstructured":"Weidle, U. H., Birzele, F., Kollmorgen, G. & Rueger, R. Mechanisms and targets involved in dissemination of ovarian cancer. Cancer Genomics Proteom. 6, 407\u2013423 (2016).","journal-title":"Cancer Genomics Proteom."},{"key":"246_CR31","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ijc.24188","volume":"9","author":"KL Sodek","year":"2009","unstructured":"Sodek, K. L., Ringuette, M. J. & Brown, T. J. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int. J. Cancer 9, 2060\u20132070 (2009).","journal-title":"Int. J. Cancer"},{"key":"246_CR32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2159-8290.CD-11-0117","volume":"2","author":"HA Kenny","year":"2011","unstructured":"Kenny, H. A., Nieman, K. M., Mitra, A. K. & Lengyel, E. The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discov. 2, 100\u2013102 (2011).","journal-title":"Cancer Discov."},{"key":"246_CR33","doi-asserted-by":"crossref","unstructured":"Coelho, R. et al. Mucins and truncated O-glycans unveil phenotypic discrepancies between serous ovarian cancer cell lines and primary tumours. Int. J. Mol. Sci. 19, 2045 (2018).","DOI":"10.3390\/ijms19072045"},{"key":"246_CR34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/2159-8274.CD-11-0010","volume":"2","author":"MP Iwanicki","year":"2011","unstructured":"Iwanicki, M. P. et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 2, 144\u2013157 (2011).","journal-title":"Cancer Discov."},{"key":"246_CR35","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1084\/jem.20180765","volume":"3","author":"Q Gao","year":"2019","unstructured":"Gao, Q. et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J. Exp. Med. 3, 688\u2013703 (2019).","journal-title":"J. Exp. Med."},{"key":"246_CR36","doi-asserted-by":"crossref","first-page":"101042831880493","DOI":"10.1177\/1010428318804937","volume":"10","author":"K Okla","year":"2018","unstructured":"Okla, K. et al. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients. Tumour Biol. 10, 1010428318804937 (2018).","journal-title":"Tumour Biol."},{"key":"246_CR37","doi-asserted-by":"crossref","unstructured":"Chen S. H., Hung W. C., Wang P., Paul C., Konstantopoulos, K. Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep. 3, 1870 (2013).","DOI":"10.1038\/srep01870"},{"key":"246_CR38","doi-asserted-by":"crossref","first-page":"26744","DOI":"10.18632\/oncotarget.15814","volume":"16","author":"S Inaguma","year":"2017","unstructured":"Inaguma, S. et al. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma. Oncotarget 16, 26744\u201326754 (2017).","journal-title":"Oncotarget"},{"key":"246_CR39","volume":"12","author":"M Kobel","year":"2008","unstructured":"Kobel, M. et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 12, e232 (2008).","journal-title":"PLoS Med."},{"key":"246_CR40","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/1541-7786.MCR-07-0254","volume":"2","author":"N Uehara","year":"2008","unstructured":"Uehara, N., Matsuoka, Y. & Tsubura, A. Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol. Cancer Res. 2, 186\u2013193 (2008).","journal-title":"Mol. Cancer Res."},{"key":"246_CR41","volume":"1","author":"X He","year":"2017","unstructured":"He, X. et al. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol. Cancer 1, 63 (2017).","journal-title":"Mol. Cancer"},{"key":"246_CR42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0014-4827(85)90197-1","volume":"2","author":"MJ Niedbala","year":"1985","unstructured":"Niedbala, M. J., Crickard, K. & Bernacki, R. J. Interactions of human ovarian tumor cells with human mesothelial cells grown on extracellular matrix. An in vitro model system for studying tumor cell adhesion and invasion. Exp. Cell Res. 2, 499\u2013513 (1985).","journal-title":"Exp. Cell Res."},{"key":"246_CR43","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1172\/JCI69815","volume":"6","author":"RA Davidowitz","year":"2014","unstructured":"Davidowitz, R. A. et al. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J. Clin. Invest. 6, 2611\u20132625 (2014).","journal-title":"J. Clin. Invest."},{"key":"246_CR44","volume":"10","author":"JN Sheets","year":"2016","unstructured":"Sheets, J. N. et al. SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. Oncogenesis 10, e264 (2016).","journal-title":"Oncogenesis"},{"key":"246_CR45","doi-asserted-by":"crossref","first-page":"25115","DOI":"10.18632\/oncotarget.25344","volume":"38","author":"KM Gharpure","year":"2018","unstructured":"Gharpure, K. M. et al. ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget 38, 25115\u201325126 (2018).","journal-title":"Oncotarget"},{"key":"246_CR46","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1349-7006.2012.02214.x","volume":"4","author":"A Shimizu","year":"2012","unstructured":"Shimizu, A. et al. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 4, 739\u2013746 (2012).","journal-title":"Cancer Sci."},{"key":"246_CR47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1541-7786.MCR-19-0688","volume":"2","author":"LR Avula","year":"2020","unstructured":"Avula, L. R. et al. Mesothelin enhances tumor vascularity in newly forming pancreatic peritoneal metastases. Mol. Cancer Res. 2, 229\u2013239 (2020).","journal-title":"Mol. Cancer Res."},{"key":"246_CR48","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1074\/jbc.M806776200","volume":"6","author":"O Kaneko","year":"2009","unstructured":"Kaneko, O. et al. A binding domain on mesothelin for CA125\/MUC16. J. Biol. Chem. 6, 3739\u20133749 (2009).","journal-title":"J. Biol. Chem."},{"key":"246_CR49","doi-asserted-by":"crossref","unstructured":"Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C., Yao, Q. Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt\/PI3K\/NF-kappaB activation and IL-6\/Mcl-1 overexpression. Mol. Cancer. 10, 106 (2011).","DOI":"10.1186\/1476-4598-10-106"},{"key":"246_CR50","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","volume":"2","author":"A Morello","year":"2016","unstructured":"Morello, A., Sadelain, M. & Adusumilli, P. S. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 2, 133\u2013146 (2016).","journal-title":"Cancer Discov."},{"key":"246_CR51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14737140.2018.1418326","volume":"2","author":"R Coelho","year":"2018","unstructured":"Coelho, R. et al. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment. Expert Rev. Anticancer Ther. 2, 177\u2013186 (2018).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"246_CR52","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"21","author":"R Hassan","year":"2014","unstructured":"Hassan, R. et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 21, 3311\u20133319 (2014).","journal-title":"Cancer"},{"key":"246_CR53","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"9","author":"C Carpenito","year":"2009","unstructured":"Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 9, 3360\u20133365 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"246_CR54","volume":"7","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z. et al. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death Dis. 7, 476 (2019).","journal-title":"Cell Death Dis."},{"key":"246_CR55","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","volume":"3","author":"E Lanitis","year":"2012","unstructured":"Lanitis, E. et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol. Ther. 3, 633\u2013643 (2012).","journal-title":"Mol. Ther."},{"key":"246_CR56","first-page":"421","volume":"2","author":"HA Azar","year":"1980","unstructured":"Azar, H. A., Hansen, C. T. & Costa, J. N:NIH(S)-nu\/nu mice with combined immunodeficiency: a new model for human tumor heterotransplantation. J. Natl Cancer Inst. 2, 421\u2013430 (1980).","journal-title":"J. Natl Cancer Inst."},{"key":"246_CR57","doi-asserted-by":"crossref","first-page":"51674","DOI":"10.18632\/oncotarget.10543","volume":"32","author":"RS Kohler","year":"2016","unstructured":"Kohler, R. S. et al. Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients. Oncotarget 32, 51674\u201351686 (2016).","journal-title":"Oncotarget"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-020-00246-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-020-00246-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-020-00246-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:07:49Z","timestamp":1670249269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-020-00246-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["246"],"URL":"https:\/\/doi.org\/10.1038\/s41389-020-00246-2","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"9 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"61"}}